Status and phase
Conditions
Treatments
About
This is a multi-center, open-label Phase 2 study designed to evaluate the efficacy and safety of BA3021 in PD-1/L1 failure patients with ROR-2 expression in recurrent or metastatic squamous cell carcinoma of the head and neck.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Patients must have measurable disease.
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
80 participants in 2 patient groups
Loading...
Central trial contact
BioAtla Medical Affairs
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal